Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in Titan Pharmaceuticals Inc as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q1 2021
- Shares held
- 581.2K
- +248.7K (+74.8%) vs. Q1 2021
- Total value
- $1.51M
- +$523.0K (+52.9%) vs. Q1 2021
- New holders
- 5
- 5 more added
- Sold out
- 6
- 6 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TTNP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $69 |
| Q1 2026 | 6 | $130 |
| Q4 2025 | 4 | $154 |
| Q3 2025 | 18 | $107.1K |
| Q2 2025 | 20 | $158.3K |
| Q1 2025 | 17 | $51.9K |
| Q4 2024 | 15 | $9.41K |
| Q3 2024 | 16 | $88.5K |
| Q2 2024 | 18 | $179.3K |
| Q1 2024 | 17 | $230.0K |
| Q4 2023 | 24 | $408.2K |
| Q3 2023 | 27 | $497.8K |
| Q2 2023 | 25 | $632.7K |
| Q1 2023 | 22 | $787.4K |
| Q4 2022 | 23 | $757.9K |
| Q3 2022 | 21 | $1.14M |
| Q2 2022 | 24 | $371.0K |
| Q1 2022 | 24 | $1.24M |
| Q4 2021 | 24 | $430.0K |
| Q3 2021 | 22 | $722.0K |
| Q2 2021 | 23 | $1.51M |
| Q1 2021 | 24 | $988.1K |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Titan Pharmaceuticals Inc; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 160 | $0 | 0.00% | −6,661−97.7% | Reduced |
| JPMorgan Chase & Co | 19 | $0 | 0.00% | −59−75.6% | Reduced |
| Wells Fargo & Company | 46 | $0 | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 60 | $0 | 0.00% | 00.0% | Unchanged |
| Lee Financial Co | 6 | $0 | 0.00% | 00.0% | Unchanged |
| Westside Investment Management, Inc. | 4 | $0 | 0.00% | −4−50.0% | Reduced |
| Advisor Group Holdings, Inc. | 15 | $0 | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 5 | $0 | 0.00% | 00.0% | Unchanged |
| Joseph P. Lucia & Associates, LLC | 2 | $0 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 1 | $0 | 0.00% | +1 | New |
| Sargent Bickham Lagudis LLC | 2 | $0 | 0.00% | +2 | New |
| Pacifica Partners Inc. | 6 | $0 | 0.00% | +6 | New |
| American Portfolios Advisors | 23 | $60 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 276 | $1.00K | 0.00% | +138+100.0% | Added |
| UBS Group AG | 8,272 | $22.0K | 0.00% | −15,187−64.7% | Reduced |
| Advisory Services Network, LLC | 9,000 | $23.0K | 0.00% | +9,000 | New |
| Bank of New York Mellon Corp | 15,397 | $40.0K | 0.00% | −2,807−15.4% | Reduced |
| Group One Trading, L.P. | 29,518 | $77.0K | 0.00% | −43,595−59.6% | Reduced |
| Virtu Financial LLC | 33,309 | $87.0K | 0.01% | +33,309 | New |
| Geode Capital Management, LLC | 53,097 | $138.0K | 0.00% | +17,582+49.5% | Added |
| Citadel Advisors LLC | 68,908 | $179.0K | 0.00% | +49,630+257.4% | Added |
| Morgan Stanley | 158,790 | $413.0K | 0.00% | +158,775+1,058,500.0% | Added |
| Vanguard Group Inc | 204,324 | $531.0K | 0.00% | +131,533+180.7% | Added |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −39,820−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −23,200−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −16,882−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −3,043−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −19−100.0% | Sold out |